Day: December 8, 2025

(In accordance with article 5 of Regulation (EU) No 596/2014 on Market Abuse Regulation and article 3(3) of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 through regulatory technical standards concerning the conditions applicable to buyback programmes and stabilisation measures) As announced on Thursday 30 October 2025, Ayvens started on Friday 31 October 2025, an ordinary share buyback programme for a maximum amount of EUR 360 million for the purpose of shares cancellation. Ayvens received all necessary authorisations from supervisory authorities. These buybacks are carried out in compliance with the conditions, notably regarding the maximum price, set forth by General Shareholders’ Meeting held on  19 May 2025 and presented in the description released on 20 May 2025, as well as in accordance with...

Cergy, December 8th 2025 – SPIE, the independent European leader in multi-technical services in the areas of energy infrastructure and communications, announces the acquisition of Cyqueo in Germany. With this step, SPIE expands its portfolio in the growing field of cybersecurity and further strengthens its consulting and integration capabilities for security solutions in complex IT infrastructures. Cyqueo, based in Munich, is a solution provider specialised in cybersecurity. The company has a broad network of partners, deep expertise in Zero Trust, cloud security, endpoint protection and managed security services, as well as long-standing customer relationships with medium-sized and large organizations. Currently, 1.6 million users are protected through Cyqueo’s solutions, which has an exceptionally high level of certification. With an...

REGULATED INFORMATION Courbevoie, France – December 8, 2025 Information on number of shares and voting rights as stipulated by article 223-16 of the general regulations of the French financial markets authority AMF Issuer: Bureau VeritasDate Number of shares (1) Number of voting rights30/11/2025 453,916,256Theoretical number of voting rights: 560,890,697           Number of exercisable voting rights: 550,627,131(1) including the new shares issued in Euroclear as a result of the exercise of stock options since January 1, 2025, if any.                Bureau Veritas Head Office Tel: + 33 (0)1 55 24 70 00Société Anonyme Tour Alto Fax: + 33 (0)1 55 24 70 01(Limited liability corporation) 4, Place des Saisons www.bureauveritas.comShare capital of EUR 54,464,582.40 92400 Courbevoie  RCS Nanterre 775 690 621 France  ...

The company did not have its case upheld in Oslo District Court and will appeal the judgmentReference is made to stock exchange announcements on January 21, 2025, and March 24, 2025, where the company reported filing a lawsuit against DnB Bank ASA, Danske Bank AS NUF, and Swedbank AB (publ). Oslo District Court has today delivered a judgment on the case. Havila Shipping does not agree with the judgment, and the district court’s ruling is not a final decision in the matter. Havila has decided to appeal the judgment within the appeal deadline in January 2026. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

CHANTILLY, Va., Dec. 08, 2025 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE:PSN), the systems integrator for the Office of Space Commerce’s (OSC) Traffic Coordination System for Space (TraCSS) program, is proud to announce that this groundbreaking advancement in space traffic coordination has been recognized with the esteemed 2025 SpaceNews Icon Award for Civil Space Achievement. This prestigious accolade underscores Parsons’ commitment to advancing safe and efficient operations in an increasingly congested orbital environment. “Receiving the SpaceNews Icon Award for Civil Space Achievement is a tremendous honor for Parsons Corporation and our Space Operations Team,” said James Johnson, senior vice president for Parsons Space Solutions Sector. “This recognition reflects the hard work of our talented teams who have been instrumental...

Patients in 200 mg BID cohort had median progression free survival of 6.2 months and median overall survival of 28.1 months, comparing favorably to results with other therapies Data supports ongoing registration Phase 3 trial in r/r PTCL, Phase 1 trial in atopic dermatitis and potential expansion into other immune and inflammatory diseases Highlights ITK inhibition novel mechanism of action affecting T cell receptor signaling and T cell differentiation Presented in an oral session at the 67th American Society of Hematology Annual Meeting & Exposition SOUTH SAN FRANCISCO, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced the presentation of final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma today in...

– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS  – Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff – – 65% (31/48) ORR in R/R NPM1-m AML, 83% (19/23) ORR in venetoclax-naïve – – 41% (13/32) ORR in R/R KMT2A-r AML, 70% (7/10) ORR in venetoclax-naïve – – Triplet combination was well tolerated in both newly diagnosed and relapsed/refractory settings; addition of ziftomenib did not increase toxicity beyond that expected with venetoclax/azacitidine alone – – Ziftomenib’s broad clinical development program spans multiple front-line and relapsed/refractory regimens across NPM1-m, FLT3-m and KMT2A-r AML subtypes – – Company-sponsored registrational trials of ziftomenib...

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest target dose tested to date; initial dose escalation results in 45 patients demonstrate a favorable safety profile across all doses assessed CLN-049 recently granted Fast Track designation by the U.S. FDA Company to host in-person event on Monday, December 8, at 8:00 p.m. ET CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today shared updated clinical data from its Phase 1 study of CLN-049, a novel, investigational...

HIAB CORPORATION, STOCK EXCHANGE RELEASE, 8 DECEMBER 2025 AT 5:00 PM (EET) Changes in Hiab Leadership Team Sanna Ahonen, EVP, Strategy and Sustainability and member of Hiab Leadership team, has decided to step down from her role. Effective immediately, her responsibilities transition to Kimberly Allan, EVP, Business Excellence. To facilitate a structured handover, Sanna will remain available upon request until 4 June 2026. “On behalf of the entire leadership team, I want to sincerely thank Sanna for her contributions to Hiab. She has played an important role in our demerger and leading our strategy and sustainability teams. I wish her every success in her future endeavours,” says Hiab’s President and CEO Scott Phillips. For further information, please contact:Birgitte Skade, Executive Vice President, Marketing and Communications,...